An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs GC 4419 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Galera Therapeutics
- 28 Feb 2018 According to Galera Therapeutics media release,Status changed from not yet recruiting to recruiting.
- 28 Feb 2018 According to Galera Therapeutics media release, first patient has been dosed.
- 26 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.